ENG
Influenza Diagnostic Market Size, Share, Growth Trends, Industry Analysis, Key Players, Investment Opportunities and Forecast (2025-2032)
Influenza Diagnostic Market was estimated at USD 1.51 Bn. in 2024 and is expected to grow at a CAGR of 7.6% from 2025 to 2032, reaching nearly USD 2.71 Bn. by 2032
Format : PDF | Report ID : SMR_2774
The global influenza diagnostic market is growing due to the increasing influenza infections. The growth is primarily driven by the fueled the need for timely and accurate detection of influenza, especially during seasonal changes and during potential pandemics. In that Rapid Influenza Diagnostic Tests are dominate the market due to their speed and ease to use. the integration of AI and machine learning in diagnostics is enhancing the speed and accuracy of results. Also, Companies are investing in FDA-approved self-testing kits that deliver results in under 30 minutes.
Hospitals represent the largest end-user segment, contributing to 48% of the global market revenue in 2024. In the influenza diagnostic market, North America holds the largest market share and covers 35% market share in 2024 The COVID-19 pandemic has also increased the demand for multiplex and rapid diagnostics, prompting public and private investments into strengthening diagnostic infrastructure for influenza and similar respiratory illnesses.
To get more Insights: Request Free Sample Report
Influenza Diagnostics Market Dynamics
Increasing Global Incidence of Influenza Outbreaks to Boost the Influenza Diagnostic Market
Based on the World Health Organization, Influenza results in 3 to 5 million serious illnesses and as many as 650,000 respiratory-related deaths every year. It has a bearing on an Increase in versions being tested during flu seasons, both laboratory-based and point-of-care testing solutions. advances in molecular diagnostics, like RT-PCR and isothermal nucleic acid amplification have greatly improved test sensitivity and specificity, driving their adoption both in clinical and point-of-care settings. The increasing rates and unpredictability of influenza viruses continue to be the most significant drivers in the influenza diagnostic market.
The Market Faces Restraints Related to Limited Accessibility of Advanced Diagnostic Technologies
A major restraint for the influenza diagnostics market is that the most accurate tests, like RT-PCR, are expensive and not easy to access especially in smaller clinics or lower-income countries. These tests cost USD 50 to USD 150 and need special machines and trained staff. rapid antigen test are much cheaper but aren't always reliable, with accuracy sometimes as low as 50–70%. The RT-PCR test unavailable in rural hospitals, small clinics, or in many low-income countries. For example, while urban hospitals may have full molecular labs, millions of people living in rural areas still depend on basic rapid tests even they are less accurate.
Home-Based Influenza Testing and Digital Health Integration is an Opportunity for Influenza Diagnostic Markets
A rapidly emerging opportunity in the influenza diagnostics market is the rise of home-based flu testing, driven by telehealth integration and smart diagnostic devices. This trend is opening doors for app-connected test kits, AI-powered symptom checkers, and remote diagnosis services. Tech-forward diagnostics companies are developing FDA-authorized home-use flu test kits, this test kits are deliver results in under 30 minutes. Some even connect directly to mobile apps, allowing patients to consult doctors virtually and get prescriptions in real-time.
Influenza Diagnostics Market Segment Analysis
Based on Product, the influenza diagnostics market is segmented into test kits and reagents, Instruments, and other products. The test kits and reagents segment dominated the market in 2024 and is expected to hold the largest market share over the forecast period (2025-2032). This dominance is driven by the high volume and repeat usage of diagnostic kits across clinical, laboratory, and at-home settings. It covers 62% of revenue in 2024, test kits are consumables required for each patient sample, leading to consistent demand. The segment includes rapid antigen kits for point-of-care use, RT-PCR and reagents for ELISA. In addition, the market access has been expanded for these products by increasing the home use kit and the government funded flu monitoring programs.
Based on Test Type, the influenza diagnostics market is segmented into Molecular Diagnostic Tests, Transcription-Mediated Amplification-Based Assay, Traditional Diagnostic Tests and others. The molecular diagnostic segment dominated the market in 2024 and is expected to hold the largest market share over the forecast period (2025-2032). This segment holds the dominant market share due to the frequent demand for testing supplies in hospitals, diagnostic centers, and increasingly at-home settings. The post-COVID-19 shift toward frequent respiratory testing growing the demand for combo kits that detect influenza alongside other viruses like SARS-CoV2 and RSV. Innovations in reagent stability and cold-chain independence are also making these products more accessible globally.
Influenza Diagnostic Market Regional Analysis:
The North America region dominated the Market in 2024 and is expected to hold the largest Market share over the forecast period (2024-2032)
The dominance of North America is primarily attributed to robust healthcare infrastructure and high diagnostic sensitivity. During the United States anticipated high volume of annual tests because of government-initiated influenza surveillance schemes and regular outbreaks during winter months. The United States and Canada possess well-established health care infrastructure with extensive availability of hospitals, clinics and clinical laboratories. Robust infrastructure lends itself for the application of highly sensitive molecular assays such as RT-PCR.
Influenza Diagnostic Market Competitive Landscape
Influenza Diagnostics Market mainly dominated some global players like Abbott Laboratories, Thermo Fisher Scientific, Quidel Corporation, Becton Dickinson. These companies hold more than 60% of the global market share in 2024, due to their comprehensive product portfolio, strong brand recognition and well -established distribution channels. These leading players invest heavy in research and development, and their main focus is on rapid and multiplex molecular clinical tests capable of detecting several respiratory viruses.
Recent development in Influenza Diagnostic Market
|
Date
|
Company |
Development |
|
April 2, 2024 |
Thermo Fisher Scientific |
Thermo Fisher announced a strategic expansion of its TaqPath Respiratory Viral Panel portfolio, including an upgraded multiplex RT-PCR assay that covers 20 respiratory targets, including flu strains. |
|
March 5, 2024 |
Becton Dickinson |
launched a new version of its Veritor Plus System with cloud-based connectivity for real-time reporting and tracking of influenza A/B, RSV, and COVID-19. |
|
February 14, 2024 |
QuidelOrtho Corporation |
QuidelOrtho announced the launch of an enhanced Sofia 2 Flu + COVID Antigen FIA in North America. |
|
January 8, 2024 |
Abbott Laboratories |
Abbott received FDA clearance for its Alinity m Resp-4-Plex assay, a multiplex molecular test that detects and differentiates between influenza A, influenza B, RSV, and COVID-19. |
|
Influenza Diagnostic Market Scope |
|
|
Market Size in 2024 |
USD 1.51 Bn. |
|
Market Size in 2032 |
USD 2.71 Bn. |
|
CAGR (2024-2032) |
7.6% |
|
Historic Data |
2019-2024 |
|
Base Year |
2024 |
|
Forecast Period |
2025-2032 |
|
Segments |
by Product Test kits and reagents Instruments Other Products |
|
by Test Type Molecular Diagnostic Tests Transcription-Mediated Amplification-Based Assay Traditional Diagnostic Tests Others |
|
|
by End-user Diagnostic Laboratories Hospitals and Clinics Others |
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe Asia Pacific – China, South Korea, Japan, India, Australia, Indonesia, Philippines, Malaysia, Vietnam, Thailand, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Key Players in the Influenza Diagnostic Market
North America
- Abbott Laboratories (United States)
- Thermo Fisher Scientific (United States)
- QuidelOrtho Corporation (United States)
- Becton, Dickinson and Company – BD (United States)
- Hologic Inc. (United States)
- Cepheid (United States)
- Meridian Bioscience (United States)
- BioFire Diagnostics (United States)
- GenMark Diagnostics (United States)
- Luminex Corporation (United States)
Europe
- Roche Diagnostics (Switzerland)
- Siemens Healthineers (Germany)
- bioMérieux SA (France)
- Randox Laboratories (United Kingdom)
- Eurofins Scientific (Luxembourg)
- DRG Diagnostics (Germany)
- Abingdon Health (United Kingdom)
- Omega Diagnostics (United Kingdom)
- Fast Track Diagnostics (Luxembourg)
- Molbio Diagnostics GmbH (Germany)
Asia-Pacific
- Sysmex Corporation (Japan)
- Fujirebio Inc. (Japan)
- Seegene Inc. (South Korea)
- SD Biosensor (South Korea)
- Mylab Discovery Solutions (India)
Frequently Asked Questions
Increasing Global Incidence of Influenza Outbreaks to Boost the Influenza Diagnostic Market.
Abbott Laboratories, Thermo Fisher Scientific, Quidel Corporation are the key competitors in the Influenza Diagnostic Market.
Home-Based Influenza Testing and Digital Health Integration is an Opportunity for Influenza Diagnostic Markets.
The test kits and reagent segment dominated the Influenza Diagnostic Market.
1. Influenza Diagnostics Market Introduction
1.1. Study Assumption and Market Definition
1.2. Scope of the Study
1.3. Executive Summary
2. Global Influenza Diagnostics Market: Competitive Landscape
2.1. SMR Competition Matrix
2.2. Competitive Landscape
2.3. Key Players Benchmarking
2.3.1. Company Name
2.3.2. Product Segment
2.3.3. Distribution Channel Segment
2.3.4. Revenue (2024)
2.4. Leading Influenza Diagnostics Market Companies, by Market Capitalization
2.5. Market Structure
2.5.1. Market Leaders
2.5.2. Market Followers
2.5.3. Emerging Players
2.6. Mergers and Acquisitions Details
3. Influenza Diagnostics Market: Dynamics
3.1. Influenza Diagnostics Market Trends by Region
3.1.1. North America Influenza Diagnostics Market Trends
3.1.2. Europe Influenza Diagnostics Market Trends
3.1.3. Asia Pacific Influenza Diagnostics Market Trends
3.1.4. Middle East & Africa Influenza Diagnostics Market Trends
3.1.5. South America Influenza Diagnostics Market Trends
3.2. Influenza Diagnostics Market Dynamics by Global
3.3. PORTER’s Five Forces Analysis
3.4. PESTLE Analysis
3.5. Value Chain Analysis
3.6. Regulatory Landscape by Region
3.6.1. North America
3.6.2. Europe
3.6.3. Asia Pacific
3.6.4. Middle East & Africa
3.6.5. South America
4. Influenza Diagnostics Market: Global Market Size and Forecast by Segmentation (by Value USD Bn) (2024-2032)
4.1. Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
4.1.1. Test kits and reagents
4.1.2. Instruments
4.1.3. Other Products
4.2. Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
4.2.1. Molecular Diagnostic Tests
4.2.2. Transcription-Mediated Amplification-Based Assay
4.2.3. Traditional Diagnostic Tests
4.2.4. Others
4.3. Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
4.3.1. Diagnostic Laboratories
4.3.2. Hospitals and Clinics
4.3.3. Others
4.4. Influenza Diagnostics Market Size and Forecast, By Region (2024-2032)
4.4.1. North America
4.4.2. Europe
4.4.3. Asia Pacific
4.4.4. Middle East & Africa
4.4.5. South America
5. North America Influenza Diagnostics Market Size and Forecast by Segmentation (by Value USD Bn) (2024-2032)
5.1. North America Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
5.1.1. Test kits and reagents
5.1.2. Instruments
5.1.3. Other Products
5.2. North America Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
5.2.1. Molecular Diagnostic Tests
5.2.2. Transcription-Mediated Amplification-Based Assay
5.2.3. Traditional Diagnostic Tests
5.2.4. Others
5.3. North America Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
5.3.1. Diagnostic Laboratories
5.3.2. Hospitals and Clinics
5.3.3. Others
5.4. North America Influenza Diagnostics Market Size and Forecast, by Country (2024-2032)
5.4.1. United States
5.4.1.1. United States Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
5.4.1.1.1. Test kits and reagents
5.4.1.1.2. Instruments
5.4.1.1.3. Other Products
5.4.1.2. United States Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
5.4.1.2.1. Molecular Diagnostic Tests
5.4.1.2.2. Transcription-Mediated Amplification-Based Assay
5.4.1.2.3. Traditional Diagnostic Tests
5.4.1.2.4. Others
5.4.1.3. United States Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
5.4.1.3.1. Diagnostic Laboratories
5.4.1.3.2. Hospitals and Clinics
5.4.1.3.3. Others
5.4.2. Canada
5.4.2.1. Canada Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
5.4.2.1.1. Test kits and reagents
5.4.2.1.2. Instruments
5.4.2.1.3. Other Products
5.4.2.2. Canada Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
5.4.2.2.1. Molecular Diagnostic Tests
5.4.2.2.2. Transcription-Mediated Amplification-Based Assay
5.4.2.2.3. Traditional Diagnostic Tests
5.4.2.2.4. Others
5.4.2.3. Canada Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
5.4.2.3.1. Diagnostic Laboratories
5.4.2.3.2. Hospitals and Clinics
5.4.2.3.3. Others
5.4.3. Mexico
5.4.3.1. Mexico Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
5.4.3.1.1. Test kits and reagents
5.4.3.1.2. Instruments
5.4.3.1.3. Other Products
5.4.3.2. Mexico Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
5.4.3.2.1. Molecular Diagnostic Tests
5.4.3.2.2. Transcription-Mediated Amplification-Based Assay
5.4.3.2.3. Traditional Diagnostic Tests
5.4.3.2.4. Others
5.4.3.3. Mexico Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
5.4.3.3.1. Diagnostic Laboratories
5.4.3.3.2. Hospitals and Clinics
5.4.3.3.3. Others
6. Europe Influenza Diagnostics Market Size and Forecast by Segmentation (by Value USD Bn) (2024-2032)
6.1. Europe Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
6.2. Europe Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
6.3. Europe Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
6.4. Europe Influenza Diagnostics Market Size and Forecast, by Country (2024-2032)
6.4.1. United Kingdom
6.4.1.1. United Kingdom Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
6.4.1.2. United Kingdom Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
6.4.1.3. United Kingdom Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
6.4.2. France
6.4.2.1. France Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
6.4.2.2. France Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
6.4.2.3. France Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
6.4.3. Germany
6.4.3.1. Germany Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
6.4.3.2. Germany Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
6.4.3.3. Germany Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
6.4.4. Italy
6.4.4.1. Italy Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
6.4.4.2. Italy Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
6.4.4.3. Italy Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
6.4.5. Spain
6.4.5.1. Spain Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
6.4.5.2. Spain Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
6.4.5.3. Spain Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
6.4.6. Sweden
6.4.6.1. Sweden Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
6.4.6.2. Sweden Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
6.4.6.3. Sweden Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
6.4.7. Austria
6.4.7.1. Austria Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
6.4.7.2. Austria Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
6.4.7.3. Austria Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
6.4.8.2. Rest of Europe Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
6.4.8.3. Rest of Europe Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7. Asia Pacific Influenza Diagnostics Market Size and Forecast by Segmentation (by Value USD Bn) (2024-2032)
7.1. Asia Pacific Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.2. Asia Pacific Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.3. Asia Pacific Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4. Asia Pacific Influenza Diagnostics Market Size and Forecast, by Country (2024-2032)
7.4.1. China
7.4.1.1. China Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.1.2. China Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.1.3. China Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.2. S Korea
7.4.2.1. S Korea Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.2.2. S Korea Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.2.3. S Korea Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.3. Japan
7.4.3.1. Japan Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.3.2. Japan Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.3.3. Japan Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.4. India
7.4.4.1. India Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.4.2. India Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.4.3. India Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.5. Australia
7.4.5.1. Australia Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.5.2. Australia Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.5.3. Australia Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.6. Indonesia
7.4.6.1. Indonesia Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.6.2. Indonesia Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.6.3. Indonesia Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.7. Philippines
7.4.7.1. Philippines Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.7.2. Philippines Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.7.3. Philippines Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.8. Malaysia
7.4.8.1. Malaysia Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.8.2. Malaysia Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.8.3. Malaysia Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.9. Vietnam
7.4.9.1. Vietnam Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.9.2. Vietnam Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.9.3. Vietnam Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.10. Thailand
7.4.10.1. Thailand Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.10.2. Thailand Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.10.3. Thailand Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.11. ASEAN
7.4.11.1. ASEAN Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.11.2. ASEAN Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.11.3. ASEAN Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
7.4.12. Rest of Asia Pacific
7.4.12.1. Rest of Asia Pacific Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
7.4.12.2. Rest of Asia Pacific Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
7.4.12.3. Rest of Asia Pacific Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
8. Middle East and Africa Influenza Diagnostics Market Size and Forecast by Segmentation (by Value USD Bn) (2024-2032)
8.1. Middle East and Africa Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
8.2. Middle East and Africa Influenza Diagnostics Market Size and Forecast, By Test Type Model (2024-2032)
8.3. Middle East and Africa Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
8.4. Middle East and Africa Influenza Diagnostics Market Size and Forecast, by Country (2024-2032)
8.4.1. South Africa
8.4.1.1. South Africa Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
8.4.1.2. South Africa Influenza Diagnostics Market Size and Forecast, By Test Type Model (2024-2032)
8.4.1.3. South Africa Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
8.4.2. GCC
8.4.2.1. GCC Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
8.4.2.2. GCC Influenza Diagnostics Market Size and Forecast, By Test Type Model (2024-2032)
8.4.2.3. GCC Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
8.4.3. Nigeria
8.4.3.1. Nigeria Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
8.4.3.2. Nigeria Influenza Diagnostics Market Size and Forecast, By Test Type Model (2024-2032)
8.4.3.3. Nigeria Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
8.4.4. Rest of ME&A
8.4.4.1. Rest of ME&A Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
8.4.4.2. Rest of ME&A Influenza Diagnostics Market Size and Forecast, By Test Type Model (2024-2032)
8.4.4.3. Rest of ME&A Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
9. South America Influenza Diagnostics Market Size and Forecast by Segmentation (by Value USD Bn) (2024-2032)
9.1. South America Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
9.2. South America Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
9.3. South America Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
9.4. South America Influenza Diagnostics Market Size and Forecast, by Country (2024-2032)
9.4.1. Brazil
9.4.1.1. Brazil Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
9.4.1.2. Brazil Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
9.4.1.3. Brazil Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
9.4.2. Argentina
9.4.2.1. Argentina Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
9.4.2.2. Argentina Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
9.4.2.3. Argentina Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
9.4.3. Rest Of South America
9.4.3.1. Rest Of South America Influenza Diagnostics Market Size and Forecast, By Product (2024-2032)
9.4.3.2. Rest Of South America Influenza Diagnostics Market Size and Forecast, By Test Type (2024-2032)
9.4.3.3. Rest Of South America Influenza Diagnostics Market Size and Forecast, By End-user (2024-2032)
10. Company Profile: Key Players
10.1 Abbott Laboratories (United States)
1.1.1. Company Overview
1.1.2. Business Portfolio
1.1.3. Financial Overview
1.1.4. SWOT Analysis
1.1.5. Strategic Analysis
1.1.6. Recent Development
10.2 Thermo Fisher Scientific (United States)
10.3 QuidelOrtho Corporation (United States)
10.4 Becton, Dickinson and Company – BD (United States)
10.5 Hologic Inc. (United States)
10.6 Cepheid (United States)
10.7 Meridian Bioscience (United States)
10.8 BioFire Diagnostics (United States)
10.9 GenMark Diagnostics (United States)
10.10 Luminex Corporation (United States)
10.11 Roche Diagnostics (Switzerland)
10.12 Siemens Healthineers (Germany)
10.13 bioMérieux SA (France)
10.14 Randox Laboratories (United Kingdom)
10.15 Eurofins Scientific (Luxembourg)
10.16 DRG Diagnostics (Germany)
10.17 Abingdon Health (United Kingdom)
10.18 Omega Diagnostics (United Kingdom)
10.19 Fast Track Diagnostics (Luxembourg)
10.20 Molbio Diagnostics GmbH (Germany)
10.21 Sysmex Corporation (Japan)
10.22 Fujirebio Inc. (Japan)
10.23 Seegene Inc. (South Korea)
10.24 SD Biosensor (South Korea)
10.25 Mylab Discovery Solutions (India)
11. Key Findings & Analyst Recommendations
12. Influenza Diagnostics Markets: Research Methodology
